Litigation Details for Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-06-28 |
| Court | District Court, D. Delaware | Date Terminated | 2019-10-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Mitchell S. Goldberg |
| Jury Demand | None | Referred To | |
| Parties | AMGEN INC. | ||
| Patents | 6,001,884; 6,011,068; 6,211,244; 6,313,146; 6,316,460; 6,495,165; 6,733,780; 6,862,890; 7,829,595; 8,288,434; 9,375,405 | ||
| Attorneys | Maryellen Noreika | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Amgen Inc. v. Accord Healthcare, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in Amgen Inc. v. Accord Healthcare, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-06-07 | 66 | Claim Construction Chart | for the asserted claims of U.S. Patent No. 9,375,405 (“the ’405 patent”). In order to narrow … e.g., ’405 patent, col.6 l.57- the ’405 patent, …: See, patent at Fig. 1, 6:57- e.g., ’405 patent, col.6 8…Evidence2 Intrinsic Evidence2 ’405 patent, “from about 1% to about “from about 1% to about… composition may contain patent at Fig. 1, 6:57- | External link to document |
| 2019-06-28 | 68 | Claim Construction Opening Brief | s ANDA product”) infringe U.S. Patent No. 9,375,405 (“the ’405 patent”). Since that time, Accord…would literally infringe the claims of the ’405 patent. The Court first rejected Amgen’s argument in its…2018 in the prior litigation involving the ’405 patent. See Amgen Inc. v. Amneal Pharms. LLC et al., …specification or prosecution history of the ’405 patent, and no indication that a person of ordinary skill…2018 21 October 2019 1:18-cv-00956 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-06-28 | 69 | Claim Construction Opening Brief | two disputed claim terms in U.S. Patent No. 9,375,405 (“the ’405 patent,” Rothman Decl. Ex. 1).1 For the… between the patent applicant and the United States Patent and Trademark Office (“Patent Office”)). Phillips…Sensipar® tablets prior to the expiration of the ’405 patent.2 On January 28, 2019, the Court entered a Scheduling…pharmaceutical compositions claimed in the ’405 Patent (“Williams Decl.”). The exhibits referenced herein…STATEMENT OF FACTS The claims of the ’405 patent are directed to pharmaceutical compositions comprising | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
